MASLD – Talk Bio

Actionable Insights Powered by AI

PathAI’s AIM-MASH AI Assist Receives Historic FDA Qualification for MASH Clinical Trials

2 days ago talkbio0Tagged AI Assist, AIM-MASH, biomarker qualification, Biopsy of liver (procedure), Clinical Trials, Drug Development Tool, EMA qualification, Histology, MASH, MASLD, metabolic dysfunction-associated steatohepatitis, Nonalcoholic Steatohepatitis, PathAI, Pathology, Qualification, United States Food and Drug Administration

PathAI; AIM-MASH; AI Assist; FDA qualification; Drug Development Tool; biomarker qualification; MASH; MASLD; NASH; metabolic dysfunction-associated steatohepatitis; AI pathology; clinical trials; EMA qualification; liver biopsy; histology

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

1 year ago talkbio0Tagged Agreement, Antibody Therapy, Artificial Intelligence, Drug Development, Eli, Eli Lilly, Insitro, MASLD, Metabolic, Metabolic Diseases, RNA, Small Interfering, steatotic liver disease, strategic

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)